Status:
TERMINATED
The Effect of Ribose on B-Type Natriuretic Peptide (BNP) Levels in Congestive Heart Failure Patients
Lead Sponsor:
Valen Labs
Conditions:
Congestive Heart Failure
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
The purpose of this research study is to test the effectiveness of CORvalen, a medical food, to increase cellular energy sufficiently to change or modify BNP levels in congestive heart failure patient...
Detailed Description
B-type natriuretic peptide (BNP), is a blood test commonly used to track the progress of congestive heart failure. CORvalen, a medical food, contains D-Ribose (ribose), a natural substance that has be...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Symptomatic adults, M/F, between 18 and 80 years of age
- BNP levels equal to or greater than 300 pg/ml.
- Primary or secondary diagnosis of congestive heart failure at the time of admission (any NYHA Class)
- Diagnosis of congestive heart failure for at least 3 months
- Able to perform 6 minute hall walk
- No therapeutic pharmaceutical class changes for at least 1 month
- Provide informed consent
- A 30-day washout period must be achieved for any patient involved in a previous clinical study.
- Exclusion
- Insulin dependent diabetes (Type I)
- History of obstructive valvular disease
- History of pulmonary hypertension within the last 3 months
- History of hypertrophic or alcoholic cardiomyopathy
- History of restrictive cardiomyopathy
- History of reversible cardiomyopathy
- History of non-compliance
- Pregnancy
- Current enrollment in any other clinical study
Exclusion
Key Trial Info
Start Date :
June 1 2006
Trial Type :
INTERVENTIONAL
End Date :
July 1 2007
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00329485
Start Date
June 1 2006
End Date
July 1 2007
Last Update
August 2 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
See list of Study Principal Investigators
Columbus, Ohio, United States